Dynamic contrast-enhanced magnetic resonance imaging and blood oxygenation level-dependent magnetic resonance imaging for the assessment of changes in tumor biology with treatment

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 103-107

  Li, Sonia P ^a   Padhani, Anwar R ^b   Makris, Andreas ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; BEVACIZUMAB; GADOLINIUM CHELATE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; DIAGNOSTIC AGENT; OXYGEN; TUMOR MARKER;

ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD OXYGENATION LEVEL DEPENDENT NUCLEAR MAGNETIC RESONANCE IMAGING; BREAST CANCER; CANCER ADJUVANT THERAPY; DENSITY; DIFFUSION WEIGHTED IMAGING; DRUG MECHANISM; DRUG MONITORING; DYNAMIC CONTRAST ENHANCED NUCLEAR MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; MATHEMATICAL MODEL; NEOVASCULARIZATION (PATHOLOGY); NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGENATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; TREATMENT RESPONSE; TUMOR CELL; TUMOR VASCULARIZATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BLOOD; BREAST TUMOR; FEMALE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CONTRAST MEDIA; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; OXYGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84855166373     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr031     Document Type: Article

References (25)

1. Padhani AR, Miles KA. Multiparametric imaging of tumor response to therapy. Radiology. 2010;256(2):348-364.
2. Zweifel M, Padhani AR. Perfusion MRI in the early clinical development of antivascular drugs: decorations of decision making tools? Eur J Nucl Med Mol Imaging. 2010;37(suppl 1):S164-S182.
3. Hayes C, Padhani AR, Leach MO. Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed. 2002;15(2):154-163.
4. Tofts PS, Brix G, Buckley DL, et al. Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging. 1999;10(3):223-232.
5. Choyke PL, Thomasson DM, Dwyer AJ, et al. Pharmacokinetic modeling of dynamic contrast enhanced MRI in cancer. In: Padhani AR, Choyke PL, eds. New Techniques in Oncologic Imaging. Boca Raton, FL: Taylor and Francis; 2006:273-290.
6. Patterson DM, Padhani AR, Collins DJ. Technology insight: water diffusion MRI-a potential new biomarker of response to cancer therapy. Nat Clin Pract Oncol. 2008;5:220-233.
7. Padhani AR, Liu G, Koh DM, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11(2):102-125.
8. Baek HM, Chen JH, Nie K, et al. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1HMR spectroscopy. Radiology. 2009;251(3):653-662.
9. Meisamy S, Bolan PJ, Baker EH, et al. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo (1)H MR spectroscopy-a pilot study at 4T. Radiology. 2004;233(2):424-431.
10. Howe FA, Robinson SP, McIntyre DJ, Stubbs M, Griffiths JR. Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed. 2001;14:497-506.
11. Ah-See MW, Makris A, Taylor NJ, et al. Early changes in functional dynamic magnetic resonance imaging predict for pathologic response to neoadjuvant chemotherapy in primary breast cancer. Clin Cancer Res. 2008;14(20):6580-6589.
12. Martincich L, Montemurro F, De Rosa G, et al. Monitoring response to primary chemotherapy in breast cancer using dynamic contrast-enhanced magnetic resonance imaging. Breast Cancer Res Treat. 2004;83(1):67-76.
13. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19(4):1195-1206.
14. Buckley DL, Drew PJ, Mussurakis S, Monson JR, Horsman A. Microvessel density of invasive breast cancer assessed by dynamic Gd-DTPA enhanced MRI. J Magn Reson Imaging. 1997;7(3):461-464.
15. Knopp MV, Weiss E, Sinn HP, et al. Pathophysiologic basis of contrast enhancement in breast tumors. J Magn Reson Imaging. 1999;10(3):260-266.
16. Su MY, Cheung YC, Fruehauf JP, et al. Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer. J Magn Reson Imaging. 2003;18(4):467-477.
17. Wedam SB, Low JA, Yang SX, et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. J Clin Oncol. 2006;24(5):769-777.
18. O'Connor JPB, Jackson A, Parker GJM, Jayson GC. DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents. Br J Cancer. 2007;96(2):189-195.
19. Hoskin PJ, Carnell DM, Taylor NJ, et al. Hypoxia in prostate cancer: correlation of BOLD-MRI with pimonidazole immunohistochemistry-initial observations. Int J Radiat Oncol Biol Phys. 2007;68(4):1065-1071.
20. Lüdemann L, Förschler A, Grieger W, Zimmer C. BOLD signal in the motor cortex shows a correlation with the blood volume of brain tumors. J Magn Reson Imaging. 2006;23(4):435-443.
21. Rakow-Penner R, Daniel B, Glover GH. Detecting blood oxygen level-dependent (BOLD) contrast in the breast. J Magn Reson Imaging. 2010;32(1):120-129.
22. Li SP, Taylor NJ, Makris A, et al. Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. Radiology. 2010;257(3):643-652.
23. McPhail LD, Robinson SP. Intrinsic susceptibility MR imaging of chemically induced rat mammary tumors: relationship to histologic assessment of hypoxia and fibrosis. Radiology. 2010;254(1):110-118.
24. Pickles MD, Gibbs P, Lowry M, Turnbull LW. Diffusion changes precede size reductions in neoadjuvant treatment of breast cancer. Magn Reson Imaging. 2006;24:843-847.
25. Yankeelov TE, Lepage M, Chakravarthy A, et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007;25(1):1-13.